342 related articles for article (PubMed ID: 28757170)
21. Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma.
Cadamuro M; Brivio S; Spirli C; Joplin RE; Strazzabosco M; Fabris L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098760
[TBL] [Abstract][Full Text] [Related]
22. Role of tissue stroma in cancer cell invasion.
De Wever O; Mareel M
J Pathol; 2003 Jul; 200(4):429-47. PubMed ID: 12845611
[TBL] [Abstract][Full Text] [Related]
23. Drug-induced bile duct injury.
Visentin M; Lenggenhager D; Gai Z; Kullak-Ublick GA
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1498-1506. PubMed ID: 28882625
[TBL] [Abstract][Full Text] [Related]
24. Advances in the generation of bioengineered bile ducts.
Justin AW; Saeb-Parsy K; Markaki AE; Vallier L; Sampaziotis F
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1532-1538. PubMed ID: 29097260
[TBL] [Abstract][Full Text] [Related]
25. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma.
Okabe H; Beppu T; Hayashi H; Horino K; Masuda T; Komori H; Ishikawa S; Watanabe M; Takamori H; Iyama K; Baba H
Ann Surg Oncol; 2009 Sep; 16(9):2555-64. PubMed ID: 19548033
[TBL] [Abstract][Full Text] [Related]
26. Repopulating the biliary tree from the peribiliary glands.
de Jong IEM; van Leeuwen OB; Lisman T; Gouw ASH; Porte RJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1524-1531. PubMed ID: 28778591
[TBL] [Abstract][Full Text] [Related]
27. Dysregulation of apoptosis in the cholangiopathies and cholangiocarcinoma.
Celli A; Que FG
Semin Liver Dis; 1998; 18(2):177-85. PubMed ID: 9606814
[TBL] [Abstract][Full Text] [Related]
28. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
29. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.
Raggi C; Invernizzi P; Andersen JB
J Hepatol; 2015 Jan; 62(1):198-207. PubMed ID: 25220250
[TBL] [Abstract][Full Text] [Related]
30. The tumour microenvironment and immune milieu of cholangiocarcinoma.
Fabris L; Perugorria MJ; Mertens J; Björkström NK; Cramer T; Lleo A; Solinas A; Sänger H; Lukacs-Kornek V; Moncsek A; Siebenhüner A; Strazzabosco M
Liver Int; 2019 May; 39 Suppl 1(Suppl 1):63-78. PubMed ID: 30907492
[TBL] [Abstract][Full Text] [Related]
31. The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma.
Zhang Y; Yan HJ; Wu J
Curr Cancer Drug Targets; 2024; 24(7):681-700. PubMed ID: 38213139
[TBL] [Abstract][Full Text] [Related]
32. Key participants of the tumor microenvironment of the prostate: an approach of the structural dynamic of cellular elements and extracellular matrix components during epithelial-stromal transition.
Gonçalves BF; Campos SG; Costa CF; Scarano WR; Góes RM; Taboga SR
Acta Histochem; 2015 Jan; 117(1):4-13. PubMed ID: 25466989
[TBL] [Abstract][Full Text] [Related]
33. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.
Sirica AE; Strazzabosco M; Cadamuro M
Adv Cancer Res; 2021; 149():321-387. PubMed ID: 33579427
[TBL] [Abstract][Full Text] [Related]
34. Epigenome dysregulation in cholangiocarcinoma.
O'Rourke CJ; Munoz-Garrido P; Aguayo EL; Andersen JB
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1423-1434. PubMed ID: 28645654
[TBL] [Abstract][Full Text] [Related]
35. Cholangiocytes: Cell transplantation.
Ridola L; Bragazzi MC; Cardinale V; Carpino G; Gaudio E; Alvaro D
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1516-1523. PubMed ID: 28735098
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
[TBL] [Abstract][Full Text] [Related]
37. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
38. An Engineered Breast Cancer Model on a Chip to Replicate ECM-Activation In Vitro during Tumor Progression.
Gioiella F; Urciuolo F; Imparato G; Brancato V; Netti PA
Adv Healthc Mater; 2016 Dec; 5(23):3074-3084. PubMed ID: 27925458
[TBL] [Abstract][Full Text] [Related]
39. Role of the bicarbonate-responsive soluble adenylyl cyclase in cholangiocyte apoptosis in primary biliary cholangitis; a new hypothesis.
Chang JC; Go S; Verhoeven AJ; Beuers U; Oude Elferink RPJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1232-1239. PubMed ID: 28962898
[TBL] [Abstract][Full Text] [Related]
40. Cholemic nephropathy - Historical notes and novel perspectives.
Krones E; Pollheimer MJ; Rosenkranz AR; Fickert P
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1356-1366. PubMed ID: 28851656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
